EXPANDING ACCESS TO HIV TREATMENT

Gilead Sciences has played a central role in expanding access to HIV treatment in the developing world, with 2016 marking the 10-year anniversary of the company’s innovative generic licensing agreements. Today, 10 million people in developing countries are receiving Gilead HIV medicines.

10 YEARS 10 MILLION PEOPLE

30,000 people on Gilead HIV medicines

2.4 million people on Gilead HIV medicines

10 million people on Gilead HIV medicines

A DECADE OF PROGRESS

• To further expand access to treatment, Gilead licenses its HIV medicines to multiple generic manufacturers
• Competition among manufacturers begins to drive down generic treatment costs
• Gilead becomes the first innovator company to join the Medicines Patent Pool
• Gilead HIV drugs are registered in 105 developing countries
• Gilead begins adding pipeline medicines to its generic licensing agreements
• Gilead HIV drugs are registered in 114 developing countries
• 18 generic manufacturers in India, South Africa and China are licensed to produce Gilead HIV medicines
• Cost of generic versions of Gilead medicines have fallen by 80% since 2006

For more information on Gilead's developing world access programs, visit http://www.gilead.com/responsibility

Gilead works with governments, NGOs, scientists, advocates, international funders and public health leaders to strengthen the response to HIV/AIDS in developing countries.

Medical education: In collaboration with ministries of health and regional business partners, Gilead provides HIV training for nurses, doctors and community health workers.

Infrastructure: With these partners, Gilead works to improve ARV supply chain management and register its HIV medicines—critical steps in expanding access to treatment.

Grantmaking: In 2016, Gilead was ranked the top corporate funder of HIV/AIDS programs worldwide by Funders Concerned About AIDS. The company's corporate contribution program provides vital support to non-profit partners that serve people living with or at risk for HIV.

For example, Gilead supports DREAMS, a partnership including PEPFAR, the Bill & Melinda Gates Foundation and others to reduce HIV infections among adolescent girls and young women in sub-Saharan Africa.

© 2016 Gilead Sciences, Inc. All rights reserved.

Gilead also supports the HIV response in the developing world by advancing the SCIENCE of treatment and building PARTNERSHIPS to extend the reach of prevention, screening and care.
To further expand access to treatment, Gilead licenses its HIV medicines to multiple generic manufacturers. Competition among manufacturers begins to drive down generic treatment costs. Gilead becomes the first innovator company to join the Medicines Patent Pool. Gilead HIV drugs are registered in 105 developing countries. Gilead begins adding pipeline medicines to its generic licensing agreements. Gilead HIV drugs are registered in 114 developing countries. 18 generic manufacturers in India, South Africa and China are licensed to produce Gilead HIV medicines. Cost of generic versions of Gilead medicines have fallen by 80% since 2006.

Gilead Sciences has played a central role in expanding access to HIV treatment in the developing world, with 2016 marking the 10-year anniversary of the company’s innovative generic licensing agreements. Today, 10 million people in developing countries are receiving Gilead HIV medicines.

New treatments: Gilead’s new generation of single tablet regimens may help reduce the cost of HIV therapy in developing countries even further.

Cure research: Gilead scientists are evaluating agents that expose dormant HIV-infected cells to the body’s immune system and may one day lead to a cure.

Prevention: Pre-exposure prophylaxis (PrEP) is being widely adopted as an important HIV prevention tool.

Implementation science: Gilead also invests in on-the-ground studies, including PrEP demonstration projects and test-and-treat pilot programs, to provide new insights that can guide prevention and treatment policy. For example, in northern Tanzania, Gilead is partnering with the Vatican to screen 300,000 people for HIV at local health centers and provide treatment to 20,000 who are diagnosed.

Through these efforts, Gilead supports the UNAIDS 90-90-90 target:
- 90% of people living with HIV knowing their status
- 90% of those diagnosed on treatment
- 90% of those treated achieving viral suppression by 2020

Gilead works with governments, NGOs, scientists, advocates, international funders and public health leaders to strengthen the response to HIV/AIDS in developing countries.

Medical education: In collaboration with ministries of health and regional business partners, Gilead provides HIV training for nurses, doctors and community health workers.

Infrastructure: With these partners, Gilead works to improve ARV supply chain management and register its HIV medicines — critical steps in expanding access to treatment.

Grantmaking: In 2016, Gilead was ranked the top corporate funder of HIV/AIDS programs worldwide by Funders Concerned About AIDS. The company’s corporate contribution program provides vital support to non-profit partners that serve people living with or at risk for HIV. For example, Gilead supports DREAMS, a partnership including PEPFAR, the Bill & Melinda Gates Foundation and others to reduce HIV infections among adolescent girls and young women in sub-Saharan Africa.

To learn more about Gilead’s developing world access programs, visit http://www.gilead.com/responsibility

© 2016 Gilead Sciences, Inc. All rights reserved.